Biomemory Acquires Catalog Assets, DNA Data Storage Commercialization Nears

Paris — French DNA data storage company Biomemory has announced the acquisition of core assets from US startup Catalog, a deal that will further accelerate the commercialization of DNA data storage technology. Biomemory plans to launch the world's first commercial DNA data storage solution for data centers in the second half of 2026.

Catalog is a US startup specializing in DNA synthesis and storage technology, holding multiple core patents in DNA data encoding and decoding. Through this acquisition, Biomemory will gain Catalog's complete technology platform and R&D team, further strengthening its technical capabilities in the DNA data storage field.

"This is an important milestone for the DNA data storage industry," Biomemory's CEO said in a statement. "By integrating Catalog's technological capabilities, we will be able to launch the world's first complete end-to-end commercial DNA data storage solution in the second half of 2026. This will make Biomemory the first company to deploy DNA storage technology in data centers."

DNA data storage is a cutting-edge technology that uses artificially synthesized DNA molecules to store digital information. Compared to traditional silicon-based storage media, DNA storage offers astonishing data density—theoretically, just one gram of DNA could store approximately 215 petabytes (215 million GB) of data. Additionally, DNA storage can preserve data for thousands of years without requiring continuous power supply.

Biomemory previously announced plans to launch its first end-to-end commercial DNA data storage service by the end of 2026. The company's DNA DRIVE product is constructed from bio-sourced components and enables ultra-high-density data storage in a remarkably small footprint. According to plans, a 100-petabyte data center storage device will be launched in 2026, significantly reducing energy consumption and space requirements compared to existing storage technologies.

Despite the promising prospects, commercialization of DNA data storage still faces many challenges. First, cost remains an issue—DNA synthesis costs remain high, with per-megabyte storage costs far exceeding traditional storage media. Second, read/write speed is a bottleneck—the DNA data writing and reading process is relatively slow and cannot yet meet real-time requirements for large-scale data access. Additionally, data integrity verification and error correction mechanisms need further refinement.

Industry analysts believe DNA storage technology is best suited for applications requiring extremely long data retention periods, massive storage capacity, and low access frequency—such as medical records, historical archives, and genetic data. For "hot data" requiring frequent access, traditional storage solutions will remain the preferred choice.

With companies like Biomemory advancing commercialization, DNA data storage technology is moving from laboratories to data centers. Industry insiders predict that if 2026 commercialization attempts succeed, the DNA storage market will experience explosive growth around 2030.

Reference Sources: TechRadar, Blocks and Files, PRNewswire